Clinicopathological features of breast cancers predict the development of leptomeningeal metastases: A case-control study

Journal of Neuro-Oncology

Volumn 105, Issue 2, 2011, Pages 309-315

  Le Rhun, Emilie ^a,b   Taillibert, Sophie ^c   Zairi, Fahed ^b   Devos, Patrick ^b,d   Pierret, Matthieu Faivre ^a   Dubois, François ^b   Assaker, Richard ^b,d   Buisset, Etienne ^a   Bonneterre, Jacques ^a,d   Baranzelli, Marie Christine ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d UNIV LILLE   (France)

Author keywords

Breast cancer; Leptomeningeal metastases

Indexed keywords

CYTARABINE; METHOTREXATE; THIOTEPA;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEPTOMENINGEAL METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT ASSESSMENT; PREDICTION; QUALITY OF LIFE;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MENINGEAL NEOPLASMS; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 82955227414     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0592-7     Document Type: Article

References (25)

1. W Boogerd 1996 Central nervous system metastasis in breast cancer Radiother Oncol 40 5 22 8844883 10.1016/0167-8140(96)01766-5 1:STN:280:DyaK2s%2FgtFyqsw%3D%3D (Pubitemid 26246261)
2. A Tosoni E Franceschi AA Brandes 2008 Chemotherapy in breast cancer patients with brain metastases: Have new chemotherapic agents changed the clinical outcome? Crit Rev Oncol Hematol 68 3 212 221 18550383 10.1016/j.critrevonc.2008.04.004
3. MD Groves 2010 New strategies in the management of leptomeningeal metastases Arch Neurol 67 3 305 312 20212228 10.1001/archneurol.2010.18
4. Chamberlain MC (2009) Leptomeningeal metastasis. Curr Opin Neurol 22(6):665-674
5. NU Lin JR Bello EP Winer 2004 CNS metastases in breast cancer J Clin Oncol 22 3608 3617 15337811 10.1200/JCO.2004.01.175 (Pubitemid 41103668)
6. CW Elston IO Elis 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 5 403 410 1757079 10.1111/j.1365-2559.1991.tb00229.x 1:STN:280:DyaK38%2FpvVSltw%3D%3D
7. AC Wolff ME Hammond JN Schwartz American Society of Clinical Oncology/College of American Pathologists, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 1 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
8. P Krauseneck 1998 Clinical relevance and current problems of neoplastic meningosis J Neurooncol 38 93 95 9696357 10.1023/A:1005973117943 1:STN:280:DyaK1czlvFGntA%3D%3D (Pubitemid 28306193)
9. AM Gonzales-Angulo M Cristofanilli EA Strom, et al. 2004 Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment Cancer 101 1760 1766 10.1002/cncr.20530 (Pubitemid 39314738)
10. K Altundag ML Bondy ND Mirza, et al. 2007 Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis Cancer 110 2640 2647 17960791 10.1002/cncr.23088 1:CAS:528:DC%2BD1cXitVOitA%3D%3D (Pubitemid 350250332)
11. MC Chamberlain 1998 Leptomeningeal metastases: a review of evaluation and treatment J Neurooncol 37 271 284 9524085 10.1023/A:1005976926058 1:STN:280:DyaK1c7ot1alsg%3D%3D (Pubitemid 28073699)
12. EL Chang MH Maor 2003 Standard and novel radiotherapeutic approaches to neoplastic meningitis Curr Oncol Rep 5 1 24 28 12493147 10.1007/s11912-003-0083- x (review) (Pubitemid 38898763)
13. CI Li JR Daling KE Malone 2003 Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998 J Clin Oncol 21 1 28 34 12506166 10.1200/JCO.2003.03.088 1:CAS:528:DC%2BD38XpvVWntrg%3D
14. AJ Evans JJ James EJ Cornford, et al. 2004 Brain metastases from breast cancer: identification of a high-risk group Clin Oncol 16 5 345 349 10.1016/j.clon.2004.03.012 1:STN:280:DC%2BD2cvjsF2lsQ%3D%3D (Pubitemid 38967255)
15. M Ryberg D Nielsen K Osterlind, et al. 2005 Predictors of central nervous system metastasis in patients with metastatic breast cancer: a competing risk analysis of 579 patients treated with epirubicin-based chemotherapy Breast Cancer Res Treat 91 3 217 225 15952055 10.1007/s10549-005-0323-x (Pubitemid 40896568)
16. YL Tham K Sexton R Kramer S Hilsenbeck R Elledge 2006 Primary breast cancer phenotypes associated with propensity for central nervous system metastases Cancer 107 696 704 16826579 10.1002/cncr.22041 (Pubitemid 44232661)
17. K Slimane F Andre S Delaloge, et al. 2004 Risks factors for brain relapse in patients with metastatic breast cancer Ann Oncol 15 11 1640 1644 15520065 10.1093/annonc/mdh432 1:STN:280:DC%2BD2crkslSksw%3D%3D (Pubitemid 39562604)
18. V Wolstenholme M Hawkins S Ashley D Tait G Ross 2008 HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients Breast 17 6 661 665 18571923 10.1016/j.breast.2008.04.006
19. A Davoli BA Hocevar TL Brown 2010 Progression and treatment of HER2-positive breast cancer Cancer Chemother Pharmacol 65 4 611 623 20087739 10.1007/s00280-009-1208-1 1:CAS:528:DC%2BC3cXotVGntA%3D%3D
20. R Lai C Dang M Malkin L Abrey 2004 The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma Cancer 101 810 816 15305414 10.1002/cncr.20418 1:CAS:528:DC%2BD2cXntlSqtbo%3D (Pubitemid 39030939)
21. E Orvieto E Maiorano L Bottiglieri, et al. 2008 Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution Cancer 113 7 1511 1520 18704988 10.1002/cncr.23811
22. EA Rakha ME El-Sayed AR Green AH Lee JF Robertson IO Ellis 2007 Prognostic markers in triple negative breast cancer Cancer 109 1 25 32 17146782 10.1002/cncr.22381 1:CAS:528:DC%2BD2sXhtVKrtLY%3D (Pubitemid 46120191)
23. S Basu W Chen J Tchou, et al. 2008 Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization Cancer 112 5 995 1000 18098228 10.1002/cncr.23226 1:CAS:528:DC%2BD1cXjs1eqsLo%3D (Pubitemid 351304582)
24. Schnitt SJ, Guidi AJ (2004) Pathology of invasive breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Disease of the breast cancer, vol 34, 3rd edn. Lippincott, Williams and Wilkins, Philadelphia, pp 541-584
25. JL Clarke HR Perez LM Jacks KS Panageas LM DeAngelis 2010 Leptomeningeal metastases in the MRI era Neurology 74 1449 1454 20439847 10.1212/WNL. 0b013e3181dc1a69 1:STN:280:DC%2BC3czgvVyktg%3D%3D